Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Verastem Inc's Business Segments
Verastem Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Research Developing and Commercialization Drugs Segment
Total Revenue
$ 19
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Research Developing and Commercialization Drugs Segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Research Developing and Commercialization Drugs Segment | $ 19 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Product100%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 19 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Verastem Inc
Verastem Inc is a biopharmaceutical company that specializes in discovering and developing small molecule drugs to treat cancer. The company is headquartered in Needham, Massachusetts, USA and was founded in 2010. Verastem Inc's focus is on developing medicines that target cancer stem cells, which are thought to be the root cause of tumor growth, recurrence, and metastasis.
The company's lead drug candidate is duvelisib, which is a dual inhibitor of PI3K-delta and PI3K-gamma. These are two enzymes that play a role in cell growth, differentiation, and survival. Duvelisib has been shown to have promising results in clinical trials for the treatment of blood cancers, such as chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and peripheral T-cell lymphoma (PTCL). The drug has received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of relapsed/refractory PTCL and FL.
Apart from duvelisib, Verastem Inc has a pipeline of drug candidates that target cancer stem cells. These include VS-6766, which is a compound that inhibits both MEK and RAF kinases, and VS-6063, which is a focal adhesion kinase (FAK) inhibitor. These drugs are being developed for the treatment of solid tumors, such as ovarian, pancreatic, and lung cancers.
Verastem Inc has collaborations with pharmaceutical companies, academic institutions, and government agencies to advance its drug development programs. The company has a partnership with Yakult Honsha Co., Ltd. for the development and commercialization of duvelisib in Japan. It has also received funding from the National Cancer Institute (NCI) for clinical trials of its drug candidates.
In terms of its financial performance, Verastem Inc reported a net loss of $83 million in 2020. The company has a market capitalization of around $300 million and a share price of around $50 as of August 202 The company has raised over $500 million in funding from investors, including private equity firms, venture capitalists, and institutional investors.
In conclusion, Verastem Inc is a biopharmaceutical company that is focused on developing drugs to target cancer stem cells. Its lead drug candidate, duvelisib, has shown promise in clinical trials for the treatment of certain types of blood cancers. The company has a pipeline of drug candidates for the treatment of solid tumors and collaborations with pharmaceutical companies and research organizations. Despite posting losses in recent years, Verastem Inc remains committed to advancing its research and development efforts to bring innovative treatments to patients with cancer.
The company's lead drug candidate is duvelisib, which is a dual inhibitor of PI3K-delta and PI3K-gamma. These are two enzymes that play a role in cell growth, differentiation, and survival. Duvelisib has been shown to have promising results in clinical trials for the treatment of blood cancers, such as chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and peripheral T-cell lymphoma (PTCL). The drug has received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of relapsed/refractory PTCL and FL.
Apart from duvelisib, Verastem Inc has a pipeline of drug candidates that target cancer stem cells. These include VS-6766, which is a compound that inhibits both MEK and RAF kinases, and VS-6063, which is a focal adhesion kinase (FAK) inhibitor. These drugs are being developed for the treatment of solid tumors, such as ovarian, pancreatic, and lung cancers.
Verastem Inc has collaborations with pharmaceutical companies, academic institutions, and government agencies to advance its drug development programs. The company has a partnership with Yakult Honsha Co., Ltd. for the development and commercialization of duvelisib in Japan. It has also received funding from the National Cancer Institute (NCI) for clinical trials of its drug candidates.
In terms of its financial performance, Verastem Inc reported a net loss of $83 million in 2020. The company has a market capitalization of around $300 million and a share price of around $50 as of August 202 The company has raised over $500 million in funding from investors, including private equity firms, venture capitalists, and institutional investors.
In conclusion, Verastem Inc is a biopharmaceutical company that is focused on developing drugs to target cancer stem cells. Its lead drug candidate, duvelisib, has shown promise in clinical trials for the treatment of certain types of blood cancers. The company has a pipeline of drug candidates for the treatment of solid tumors and collaborations with pharmaceutical companies and research organizations. Despite posting losses in recent years, Verastem Inc remains committed to advancing its research and development efforts to bring innovative treatments to patients with cancer.
Verastem Inc. is a biopharmaceutical company committed to advancing the treatment landscape for cancer patients through innovative therapies. Operating within the highly specialized segment of cancer therapeutics, the company focuses on the discovery and development of small molecule drugs that specifically target critical signaling pathways implicated in the growth and proliferation of cancer cells.
Segments
Verastem Inc. functions within a singular, well-defined segment focused on the development and commercialization of innovative cancer treatments. This segment caters predominantly to the biopharmaceutical industry while also encompassing a range of stakeholders, including healthcare providers such as oncologists and treatment centers, patients diagnosed with cancer, and various organizations involved in cancer research and treatment.
Products
Verastem has developed a portfolio of products designed to address specific cancer types through targeted therapy approaches:
1. Copiktra (Duvelisib):
- Overview: Copiktra is a selective, small molecule inhibitor that disrupts several critical signaling pathways essential for the survival and proliferation of cancer cells. This product specifically inhibits the PI3K (phosphoinositide 3-kinase) pathway and the dual inhibition of PI3K-delta and PI3K-gamma.
- Indications: It is approved for the treatment of adults with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), as well as for adult patients with relapsed or refractory Follicular Lymphoma (FL) who have undergone at least two prior systemic therapies.
- Mechanism of Action: By targeting the unique signaling pathways that support tumor cell survival, Copiktra helps to inhibit further cancer progression while also fostering apoptosis (programmed cell death) in affected cells.
2. VS-6766:
- Overview: VS-6766 is an investigational small molecule that acts as a dual inhibitor of the MAP kinase (MAPK) pathway, specifically targeting both RAF and MEK kinases. This dual activity is intended to disrupt the signaling cascade that promotes cancer cell proliferation.
- Clinical Development: The drug is currently under evaluation in clinical trials for various types of solid tumors, including melanoma, colorectal cancer, and non-small cell lung cancer (NSCLC). These trials assess the efficacy of VS-6766 both as a monotherapy and in combination with other treatments.
- Potential Impact: By addressing the MAPK pathway, VS-6766 represents a promising approach for overcoming resistance mechanisms that often limit the effectiveness of existing cancer therapies.
Services
In addition to its product offerings, Verastem Inc. provides a suite of services designed to enhance the overall drug development process:
1. Clinical Development Services:
- Verastems clinical development services encompass a comprehensive approach to the design and execution of clinical trials. The companys experienced team is responsible for developing clinical trial protocols, managing the logistics of trial implementation, and analyzing resulting data. This data is crucial for regulatory submissions and ultimately for the approval process of new therapeutic agents.
2. Medical Affairs:
- The medical affairs team at Verastem strives to bridge the gap between scientific research and practical application. They supply vital clinical and scientific information to healthcare professionals and patients, ensuring that stakeholders are informed about the latest therapeutic options. This team also plays a critical role in establishing and maintaining collaborations with other entities in the healthcare ecosystem, including academic institutions and research organizations.
3. Commercialization:
- The commercialization services focus on the marketing and distribution of Verastems products. The team develops tailored marketing strategies aimed at effectively reaching healthcare providers and educating them about the clinical benefits and uses of the company’s therapies. Partnerships with key stakeholders, including distributors and healthcare organizations, are managed through this segment to ensure broad access to Verastem’s innovative treatments.
Conclusion
Verastem Inc. stands at the forefront of cancer therapy innovation, dedicated to improving patient outcomes through its carefully developed products, including Copiktra and VS-6766. The company supports these products with robust services in clinical development, medical affairs, and commercialization, establishing a comprehensive approach to addressing the needs of cancer patients and the wider healthcare community. Through the strategic targeting of critical signaling pathways within cancer cells, Verastem continues to explore new therapeutic avenues, striving to make meaningful contributions to cancer treatment options.
Segments
Verastem Inc. functions within a singular, well-defined segment focused on the development and commercialization of innovative cancer treatments. This segment caters predominantly to the biopharmaceutical industry while also encompassing a range of stakeholders, including healthcare providers such as oncologists and treatment centers, patients diagnosed with cancer, and various organizations involved in cancer research and treatment.
Products
Verastem has developed a portfolio of products designed to address specific cancer types through targeted therapy approaches:
1. Copiktra (Duvelisib):
- Overview: Copiktra is a selective, small molecule inhibitor that disrupts several critical signaling pathways essential for the survival and proliferation of cancer cells. This product specifically inhibits the PI3K (phosphoinositide 3-kinase) pathway and the dual inhibition of PI3K-delta and PI3K-gamma.
- Indications: It is approved for the treatment of adults with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), as well as for adult patients with relapsed or refractory Follicular Lymphoma (FL) who have undergone at least two prior systemic therapies.
- Mechanism of Action: By targeting the unique signaling pathways that support tumor cell survival, Copiktra helps to inhibit further cancer progression while also fostering apoptosis (programmed cell death) in affected cells.
2. VS-6766:
- Overview: VS-6766 is an investigational small molecule that acts as a dual inhibitor of the MAP kinase (MAPK) pathway, specifically targeting both RAF and MEK kinases. This dual activity is intended to disrupt the signaling cascade that promotes cancer cell proliferation.
- Clinical Development: The drug is currently under evaluation in clinical trials for various types of solid tumors, including melanoma, colorectal cancer, and non-small cell lung cancer (NSCLC). These trials assess the efficacy of VS-6766 both as a monotherapy and in combination with other treatments.
- Potential Impact: By addressing the MAPK pathway, VS-6766 represents a promising approach for overcoming resistance mechanisms that often limit the effectiveness of existing cancer therapies.
Services
In addition to its product offerings, Verastem Inc. provides a suite of services designed to enhance the overall drug development process:
1. Clinical Development Services:
- Verastems clinical development services encompass a comprehensive approach to the design and execution of clinical trials. The companys experienced team is responsible for developing clinical trial protocols, managing the logistics of trial implementation, and analyzing resulting data. This data is crucial for regulatory submissions and ultimately for the approval process of new therapeutic agents.
2. Medical Affairs:
- The medical affairs team at Verastem strives to bridge the gap between scientific research and practical application. They supply vital clinical and scientific information to healthcare professionals and patients, ensuring that stakeholders are informed about the latest therapeutic options. This team also plays a critical role in establishing and maintaining collaborations with other entities in the healthcare ecosystem, including academic institutions and research organizations.
3. Commercialization:
- The commercialization services focus on the marketing and distribution of Verastems products. The team develops tailored marketing strategies aimed at effectively reaching healthcare providers and educating them about the clinical benefits and uses of the company’s therapies. Partnerships with key stakeholders, including distributors and healthcare organizations, are managed through this segment to ensure broad access to Verastem’s innovative treatments.
Conclusion
Verastem Inc. stands at the forefront of cancer therapy innovation, dedicated to improving patient outcomes through its carefully developed products, including Copiktra and VS-6766. The company supports these products with robust services in clinical development, medical affairs, and commercialization, establishing a comprehensive approach to addressing the needs of cancer patients and the wider healthcare community. Through the strategic targeting of critical signaling pathways within cancer cells, Verastem continues to explore new therapeutic avenues, striving to make meaningful contributions to cancer treatment options.